Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 154

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 154
---
, each C Deferred Share has very limited rights
and is effectively valueless. The C Deferred Shares have the rights and restrictions as set out in the Articles of Association and do
not entitle the holder thereof to receive notice of or attend and vote at any general meeting of the Company or to receive a dividend
or other distribution.

Registered Direct Offering and Concurrent Private Placement

On
July 22, 2024, we completed the closing of the July 2024 Registered Direct Offering and the July 2024 Private Placement with certain Investors,
for the sale of (i) an aggregate of 202,032 Depositary Shares, and (ii) an aggregate of 11,157 pre-funded warrants exercisable for Depositary
Shares, or the July 2024 Pre-Funded Warrants, at a price per Depositary Share of $23.50, and a price per July 2024 Pre-Funded Warrant
of $23.4975. The aggregate gross proceeds to us were approximately $5.0 million, before deducting the placement agent’s fees and related offering expenses.

| 78 |

TheJuly
2024 Pre-Funded Warrants were sold, in lieu of Depositary Shares, to the Investors such that the Investors’ purchase of Depositary Shares in the Registered Direct Offering would not otherwise result in the Investor, together with their affiliates and certain related parties, beneficially owning more than 4.99% or 9.99% of our Ordinary Shares immediately following the consummation of the July 2024 Registered Direct Offering. EachJuly 2024 Pre-Funded Warrant represents the right to purchase one Depositary Share at an exercise price of $0.0025 per share. TheJuly 2024 Pre-Funded Warrants are exercisable immediately and may be exercised at any time until theJuly 2024 Pre-Funded Warrants are exercised in full.

Additionally,
in the concurrent July 2024 Private Placement, we issued and sold to the Investors (i) Series J Warrants exercisable for 213,188 Depositary
Shares, and (ii) Series K Warrants to purchase an aggregate of 213,188 Depositary Shares. The warrants are immediately exercisable at
an exercise price of $25.00 per Depositary Share, subject to adjustments for certain dilutive equity issuances. The Series J Warrants
will expire five years from the initial exercise date and the Series K Warrants will expire one year from the initial exercise date. The
Invest